Joris D. Veltman

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

Joris D. Veltman, Margaretha Lambers, Menno van Nimwegen et al. · BMC Cancer · 2010 · 285 citations · Full text

Medicine, Oncology, Pharmacology +16

Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma

Joost P. Hegmans, Joris D. Veltman, Margaretha Lambers et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 141 citations · Full text

Life Sciences, Immunology, Oncology +17

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

Joris D. Veltman, Margaretha Lambers, Menno van Nimwegen et al. · British Journal of Cancer · 2010 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study

Sayed M.S. Hashemi, Marieke F. Fransen, Anna-Larissa N. Niemeijer et al. · Lung Cancer · 2021 · 71 citations · Full text

Life Sciences, Immunology, Oncology +17

Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors

Martine Cools, Friedemann Honecker, Hans Stoop et al. · Human Pathology · 2005 · 58 citations

Life Sciences, Developmental Biology, Genetics +17